September 22, 2014: In the persistent struggle to raise their companies’ stock prices, CEOs relentlessly search for the most effective strategies to bring value to a company while keeping the bottom line lean and mean.
September 22, 2014: Merck and Sigma-Aldrich have entered into a definitive agreement under which Merck will acquire Sigma-Aldrich for $17.0 billion, establishing one of the leading players in the $130 billion global life science industry.
September 22, 2014: Regeneron has quickly become one of the world's biggest biotech companies thanks to its Eylea treatment for macular degeneration, but its little known experimental allergy drug could become equally successful, senior company executives said in interviews.
September 22, 2014: Venture capital firm Avalon Ventures announced today they are launching two new life science companies in partnership with GSK. The two new companies, each of which will receive $10 million in Series A financing, are Silarus Therapeutics and Thyritope Biosciences.